The Use of Infliximab in Dermatology

Author(s): Melda Demirtasoglu, Emel Fetil

Journal Name: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Formerly Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents

Volume 6 , Issue 3 , 2007

Become EABM
Become Reviewer
Call for Editor


Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-α) which is major cytokine playing pivotal role in inflammatory diseases. Efficacy and safety of infliximab was studied in numerous inflammatory skin diseases where TNF-α is involved in pathogenesis especially in psoriasis and psoriatic arthritis. This review summarizes the current data revealing the efficacy and safety of infliximab in treating various dermatoses beyond its approved indications. Results of clinical trials and case reports suggest that infliximab is a promising agent in treating inflammatory cutaneous dermatoses where conventional therapies fail to respond or have limited effect due to potential side effects.

Keywords: Infliximab, tumor necrosis factor-α, psoriasis, cutaneous dermatoses

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [188 - 204]
Pages: 17
DOI: 10.2174/187152307781368283
Price: $65

Article Metrics

PDF: 8